Trajan and University of Adelaide's IPAS partnership video
Watch to find out how the strategic collaboration between Trajan Scientific and Medical (Trajan) and the University of Adelaide's Institute for Photonics and Advanced Sensing (IPAS) came into being.
The video features Trajan's CEO Mr Stephen Tomisich, and Dr Anne Collins, General Manager of Trajan's Instruments, Sensors and Devices business unit; outlining why IPAS was chosen as an ideal location for collaborating on specialty glass products for the global science and medical equipment market.
IPAS Deputy Director Prof Heike Ebendorff-Heidepriem, and IPAS Institute Manager, Mr Piers Lincoln, also discuss the benefits for universities working with a global commercial partner such as Trajan.
Sneak a peek into the state of the art facilities in the video below, and subscribe to Trajan's YouTube channel, and IPAS' YouTube channel.
Related news
2016 Science Excellence Awards SA
University’s partnership proves Agenda’s strengths
Trajan announces landmark collaboration in R&D and manufacturing with Australian academia and government
More information
The University of Adelaide
Media contact information
Trajan Scientific and Medical
media@trajanscimed.com
+44 (0) 1244 403 100
 and the University of Adelaide's Institute for Photonics and Advanced Sensing (IPAS) came into being.
The video features Trajan's CEO Mr St...&media=//cdn.shopify.com/s/files/1/0767/9441/articles/Trajan_38_600x.jpg?v=1477996927){kind=link}
Also in News
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
European patent for Trajan’s hemaPEN
US FDA listing of Trajan’s hemaPEN blood microsampling device
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.